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Abstract The allele 1691A F5 , conferring Factor V Leiden,
is a common risk factor in venous thromboembolism. The
frequency distribution for this allele in Western Europe has
been well documented; but here data from Central, Eastern
and South-Eastern Europe has been included. In order to
assess the significance of the collated data, a chi-squared test
was applied, and Tukey tests and z-tests with Bonferroni
correction were compared. Results: A distribution with a
North-Southeast band of high frequency of the 1691A F5
allele was discovered with a pocket including some Southern
Slavic populations with low frequency. European countries/
regions can be arbitrarily delimited into low (group 1, <2.8 %,
mean 1.9 % 1691A F5 allele) or high (group 2, ≥2.8 %, mean
4.0 %) frequency groups, with many significant differences
between groups, but only one intra-group difference (the
Tukey test is suggested to be superior to the z-tests). Conclu-
sion: In Europe a North-Southeast band of 1691A F5 high
frequency has been found, clarified by inclusion of data from
Central, Eastern and South-Eastern Europe, which surrounds
a pocket of low frequency in the Balkans which could
possibly be explained by Slavic migration. There seem to be
no indications of variation in environmental selection due to
geographical location.
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Introduction
The gene F5 encodes for blood coagulation Factor V, and the
1691G>A F5 transition in exon 10 causes a substitution
(R506Q) known as Factor V Leiden. This genetic variant is
the most common hereditable risk factor for thromboembolic
disease (Kujovich 2011). Clinical observations with the
1691A F5 allele include an increased risk of deep vein throm-
bosis (Koster et al. 1993; Ridker et al. 1998; Rosendorff and
Dorfman 2007), and 1691A F5 is also associated with an
increased risk for pregnancy loss and possibly other obstetric
complications (Ridker et al. 1998; Foka et al. 2000), these
effects being semi-dominant.
The 1691A F5 allele is thought to have originated with a
single mutation event which took place 21,000–34,000 years
ago (Zivelin et al. 1997). The 1691A F5 allele appears to be
generally confined to Indo-Europeans: the 1691A allele is
very rare or non-existent in Asia (0.6 %) and some regions
of Africa (0.0 %) (Hira et al. 2002; Nasiruddin et al. 2005;
They-They et al. 2010); but note that Settin et al. (2008)
reported a frequency of 10.2 % in Egypt. In various parts of
Europe the frequency of this variant has been described as
uneven (Rees et al. 1995; Herrmann et al. 1997; Paseka et al.
2000; Adler et al. 2010), with high frequencies observed in the
Czech Republic (5.1 %, n =2819) (Prochazka et al. 2003) and
Turkey (5.0 %, n =2003) (see Fig.1 for references).
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We provide a summary study of the frequency distribution
of 1691A F5 across Europe by addition of values from 12
countries/regions which are predominantly populated by Slav-
ic populations (note that Serbia and Montenegro separated in
2006 - data in this article precede this date).
Materials and methods
The databases Medline (U.S. National Library of Medicine,
Bethesda, USA) and several websites providing local language
articles (e.g., www.google.ba for Bosnia/Herzegovina, www.
google.hr for Croatia; Google Inc., Mountain View, California,
USA) were searched until March 2012. Keywords and/or mesh
terms used were (together with country/region names): “1691A
F5”, “Leiden”, “FV’, “F5”, “FVL”, “Factor 5”, “fv”. Data for
Bosnia/Herzegovina were obtained from our previous study
(Valjevac et al. 2013). Data were included from: groups of
blood donors, those defined as “healthy” adults in case–control
studies, and population groups. Summary data in Europe for
NM_000130.4:c.1691G>A F5 is presented as a map.
In order to test the significance of the resulting distribution,
a chi-squared test for independence (Ulukus et al. 2006) and
post-hoc pair-wise proportion comparison tests were carried
out between all countries by two methods: (1) as in Zar
(1999): tests analogous to, and refered to here as, “Tukey
tests” (critical values from R package DKT; Lau 2011); (2)
z-tests with Bonferroni correction (Microsoft Excel 2007,
Redmond, WA, USA; http://www.csun.edu/~vchsc006/469/
z.html). The critical significance level was set at p =0.05.
Results
A map showing average frequencies for 1691A F5 through-
out Europe is given in Fig. 1a.
Comparison of the 1691A F5 allele frequency values in all
populations, assessed by the chi-squared test, gave a
Fig. 1 a . Average allele frequencies for 1691A F5 across Europe. b .
Significant differences between countries. a . 1691A F5 frequencies:
>3 %, <3 % (n.d. = no data). Slavic data (Adler et al. 2012):
Poland n =1588, Czech Republic n =2819, Slovakia n =152, Slovenia
n =526, Croatia n =749, Serbia/Montenegro n=499;Macedonia n =130,
Bulgaria n =506, Russia n =539, Ukraine n =172, Belarus n =80;
Bosnia/Herzegovina n =67 (Valjevac et al. 2013). Other data: Group 1 :
Albania (n =70; Arsov et al. 2006), Austria (n=572; Gisslinger et al.
1995, Lalouschek et al. 2005), Finland (n =1285; Hiltunen et al. 2007),
France (n=1242; Leroyer et al. 1997; Baba-Ahmed et al. 2007; Pasquier
et al. 2009), Iceland (n =96; Rees et al. 1995), Netherlands (n =2631;
Rosendaal et al. 1995; Heijmans et al. 1998; van Dunne et al. 2006),
Portugal (n =303; Ferrer-Antunes et al. 1995; Serrano et al. 2011), Spain
(n =889; Garcia-Gala et al. 1997; Aznar et al. 2000; Frances et al. 2006),
Switzerland (n =100; Redondo et al. 1999). Group 2 : Denmark
(n =20242; Larsen et al. 1998; Juul et al. 2002; Benefield et al. 2005),
Germany (n =2199; Aschka et al. 1996; Schambeck et al. 1997; Nabavi
et al. 1998; Ehrenforth et al. 1999; Lichy et al. 2006; Toth et al. 2008),
Greece (n=932; Foka et al. 2000; Rees et al. 1995; Lambropoulos et al.
1997; Antoniadi et al. 1999; Ioannou et al. 2000; Aronis et al. 2002;
Komitopoulou et al. 2006), Hungary (n =1196; Tordai et al. 1997;
Stankovics et al. 1998; Szolnoki et al. 2001; Shemirani et al. 2011), Italy
(n =226; De Stefano et al. 1999; Sottilotta et al. 2009), Norway
(n =807; Ulvik et al. 1998; Berge et al. 2007), Romania (n=42; Fischer
et al. 2006), Sweden (n =1343; Svensson et al. 1997; Kjellberg et al.
2010), Turkey (n =2003; Ozbek and Tangun 1996; Akar et al. 1997;
Gurgey and Mesci 1997, Atasay et al. 2003; Agaoglu et al. 2005; Eroglu
et al. 2006; Ulukus et al. 2006), U.K. (n =491; Rees et al. 1995; Catto
et al. 1999). b . Significant differences (p <0.05) between 1691A F5 allele
frequency values in European countries, as analyzed by Tukey tests.
Capital letters indicate countries with high frequency values significantly
different from at least one country; lower case letters indicate which
countries had significantly different, and lower, allele frequencies than
those with the corresponding capital letter
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significant value (p <0.001) showing the presence of differ-
ences between countries/regions.
The thick line in Fig. 1 arbitrarily delimits a group of
countries with low frequency (group 1) from those with high
frequency (group 2), with an arbitrary cut-off at 2.8 %. Al-
though this was an arbitrary cut-off, with post-hoc Tukey and
z-tests the two groups of countries/regions were found to have
only one intra-group significant difference (between Czech
Republic, 5.1 %, n =2819; and Denmark, 3.9 %, n =20242),
but many significant differences between the groups (Fig.1b).
Group 1 consisted of countries/region with 1691A F5
allele frequency <2.8 %; the average frequency in the group
was 1.9 %. Countries in group 1 included: Russia, Finland,
Ukraine, Poland, Slovenia, Serbia/Montenegro, Croatia, The
Netherlands, France, Spain, Portugal (these countries have
reasonable sample sizes, and each has at least one significant
difference with another country’s value). If those countries
with no significant differences at all (with smaller sample
sizes) were included, then this group consisted of most (ten)
Slavic populations together with another eight non-Slavic
countries (Fig.1).
Group 2 consisted of countries with 1691A F5 allele
frequency ≥2.8 %; the average frequency in the group was
4.0 %: Countries with at least one pair-wise significant differ-
ence by Tukey tests included: Sweden, Norway, Denmark,
Germany, U.K., The Czech Republic, Austria, Hungary, Italy,
Bulgaria, Greece and Turkey. Including those countries with
no significant differences at all (with small sample sizes), this
group consisted of 13 countries including the predominantly
Slavic countries Czech Republic and Bulgaria (Fig. 1).
Tukey tests and z-tests gave similar numbers of pair-wise
differences between countries (66 and 59, respectively; Tukey
test results are shown in Fig.1b.; z-test results not shown).
However, the Tukey tests defined statistically significant dif-
ferences involving Slovenia (2.5 %, n =526), Russia (2.4 %,
n =539) and Serbia and Montenegro (2.2 %, n =499), which
were not identified using z-tests, whereas z-tests defined dif-
ferences involving Romania (8.3 %, n =42 - note the very
small sample size). Additionally the other Tukey test differ-
ences were more evenly distributed whereas with z-tests most
differences were concentrated on Spain (2.0 %, n =889), and
Finland (1.1 %, n =1285).
Discussion
In Europe the average 1691A F5 allele frequency was found
to be 3.5 % (n =44,627, references in Fig.1).
In order to highlight the distribution of high frequency
populations, European countries/regions were arbitrarily di-
vided into two groups: with low (group 1) or high frequency
(group 2), with an arbitrary boundary at 2.8 % (delineated by
thick lines in Fig. 1). The group of high frequency countries
(i.e., group 2) was found to have a North-Southeast band
distribution. A pocket of low frequency with some Southern
Slavic countries (Slovenia, Croatia, Bosnia and Herzegovina,
and Serbia and Montenegro) and Albania (although note low
sample size) was found to be enclosed by this band of high
frequency. We can therefore surmise that the band of high
frequency was created by founder effect seeding, and the
pocket of low frequency might have been created with the
purported movement of Eastern Slavic populations with low
frequency to this region in the fifth to seventh centuries.
However, conclusions referring to the migration of Slavic
peoples have to take into account the fact that the Czech
Republic and Bulgaria have high frequencies of this allele.
Especially note that the Czech Republic has the highest fre-
quency value in Europe (5.1 %; with a reasonable sample size
of 2819) but note that this value is not significantly different to
values in the neighboring countries Germany and Austria.
Additionally, therefore, it could be hypothesized that these
result from high influx of peoples carrying the variant from
neighboring populations.
It is not known to what extent positive or negative selection
acts on this allele - it is thought that the negative impact of
1691A F5 before reproductive age exists but reports in chil-
dren are scanty (El-Karaksy and El-Raziky 2011). From the
North-Southeast band of high frequency of the 1691A F5
allele there seem to be no indications of possible environmen-
tal effects which could vary according to location (and act as
selection) on this allele.
Although such a map in Fig. 1 is informative, the statistical
significance of the distribution found depends directly on the
sample sizes of the data (see legend to Fig.1). Additionally,
there are several ways to do post-hoc pair-wise comparison
tests between countries, which take into account sample sizes.
By using Tukey tests or z-tests it was found that there was only
one intra-group significant difference (within group 2 between
Czech Republic and Denmark; Fig.1b), but many significant
differences between groups. (Significance maps at the p =0.01
level, for either test, were very similar - not shown.)
This means that inferences from individual country values
should be made with caution, and the high frequency group of
countries could be treated more or less as one block (and
likewise for the low frequency group). The map in Fig. 1
represents the present state of knowledge concerning the
distribution of the 1691G>A F5 allele, and theoretically in-
creasing the sample sizes would increase the number of pair-
wise statistical differences shown in Fig.1b. It should be
noted, however, that several sample sizes are already reason-
ably large e.g., The Netherlands (2.2 %, n =2631), Germany
(3.8 %, n =2199) but show no intra-group significant differ-
ences by either of the methods used.
Despite the overall similarities in the conclusions drawn
from the Tukey and z-tests, it should be noted that these
analyses suggest (and confirm) the appropriateness of Tukey
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tests, rather than z-tests with Bonferroni correction, for this
type of study. The reason for this is that any inference from
differences involving Romania with only 42 subjects is rather
dubious (as is the rather high allele sample frequency of 8.3%,
which might not be a good representation of the frequency in
the population). The z-tests, however, gave six differences,
between Romania and: Finland, Poland, Ukraine, Croatia,
Spain, and Portugal (data not shown), whereas the Tukey tests
gave no significant differences involving Romania (Fig.1b).
The clinical effects of the 1691A F5 variant are fairly well
established, with a three to eight-fold increased thrombotic
risk for heterozygotes, and up to 80-fold increased risk for
homozygotes, found in a pooled analysis of eight case–control
studies with over 2300 cases from Western European coun-
tries (Emmerich et al. 2001). In a Croatian case–control study
(with 160 cases) a high frequency of thromboembolism was
also found to be associated with the 1691A F5 allele: 21 % of
patients with venous thromboembolism carried the 1691A F5
allele, but only 4 % of healthy controls (Coen et al. 2001).
Further studies could be done to confirm whether or not the
presence of the 1691A F5 allele does indeed provide a similar
risk for venous thromboembolism across Europe.
Conclusions
In summary, a North-Southeast band distribution of 1691A
F5 high frequency in Europe was found by the addition of
data collated and presented from Central, Eastern and South-
Eastern Europe. A pocket of low frequency in some Southern
Slavic countries was found to be enclosed by this band of high
frequency. The reasons for this distribution are not known, but
perhaps reflect founder effects following migration after the
last ice age, followed by the migration of Slavic peoples from
the fifth century. There seem to be no indications of variation
in environmental selection due to geographical location.
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